menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Optimizing Erythropoietic Therapy for CKD

close
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    How are erythropoietic-stimulating agents (ESA) most helpful for patients with chronic kidney disease? What target levels of iron should clinicians maintain before starting ESA therapy, and what challenges will we encounter in this process? Host Dr. Charles Turck probes these questions and more with Dr. Sarah Tomasello, clinical associate professor at the Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey, and a clinical specialist in nephrology at Robert Wood Johnson University Hospital in New Jersey.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    How are erythropoietic-stimulating agents (ESA) most helpful for patients with chronic kidney disease? What target levels of iron should clinicians maintain before starting ESA therapy, and what challenges will we encounter in this process? Host Dr. Charles Turck probes these questions and more with Dr. Sarah Tomasello, clinical associate professor at the Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey, and a clinical specialist in nephrology at Robert Wood Johnson University Hospital in New Jersey.

Facebook Comments

Schedule25 Oct 2021
Webpack App